UBS analyst David Dai raised the firm’s price target on Perspective Therapeutics (CATX) to $8 from $7 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress
- Perspective Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside
- Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline
- Midday Fly By: Disney slips despite Q1 beat, Devon to combine with Coterra